One-liner#

IBS management centers on positive diagnosis using Rome IV criteria, limited testing to exclude organic disease, dietary modification (low-FODMAP diet effective in 50-80%), and subtype-specific pharmacotherapy (loperamide/rifaximin for IBS-D; linaclotide/PEG for IBS-C; neuromodulators for pain-predominant).

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

Rome IV Criteria for IBS: Recurrent abdominal pain ≥1 day per week in the last 3 months, associated with ≥2 of:

• Related to defecation (improves or worsens)
• Associated with change in stool frequency
• Associated with change in stool form (appearance)

Symptom onset ≥6 months before diagnosis.

IBS Subtypes (based on Bristol Stool Scale on days with abnormal stools):

Key diagnostic points:

• IBS is a positive diagnosis—make it based on Rome IV criteria, not exclusion
• Alarm features warrant additional workup but do not exclude IBS
• Subtype may change over time; reassess periodically

Epidemiology#

Prevalence is 10-15% globally; affects women 1.5-2x more than men. Peak onset in 20s-30s; less common to develop after age 50 (new onset in older adults warrants more extensive workup). Risk factors include female sex, younger age, prior GI infection (post-infectious IBS in 10-15%), psychological stress, anxiety, depression, and family history. IBS accounts for 25-50% of GI referrals and significantly impacts quality of life and work productivity. Does NOT increase risk of colorectal cancer, IBD, or mortality.

Pathophysiology#

Mechanism (clinical understanding)#

IBS results from dysfunction in the gut-brain axis—the bidirectional communication between the central nervous system and the enteric nervous system. Multiple mechanisms contribute:

Visceral hypersensitivity:

• Heightened perception of normal gut sensations (distension, contractions)
• Lower pain thresholds to rectal balloon distension in studies
• Explains why patients feel pain with normal amounts of gas or stool
• Central sensitization amplifies peripheral signals

Altered gut motility:

• IBS-D: accelerated colonic transit, increased high-amplitude propagating contractions
• IBS-C: delayed colonic transit, reduced propagating contractions
• IBS-M: alternating patterns
• Motility changes correlate with symptoms but don’t fully explain them

Gut-brain axis dysfunction:

• Stress activates the hypothalamic-pituitary-adrenal (HPA) axis
• Corticotropin-releasing factor (CRF) increases colonic motility and visceral sensitivity
• Autonomic nervous system dysregulation (sympathetic/parasympathetic imbalance)
• Explains strong association with anxiety, depression, and stress

Intestinal permeability and immune activation:

• Increased intestinal permeability (“leaky gut”) in subset of patients
• Low-grade mucosal inflammation with increased mast cells
• Elevated cytokines in some patients
• May explain post-infectious IBS (10-15% develop IBS after acute gastroenteritis)

Microbiome alterations:

• Dysbiosis (altered gut bacteria composition) in many IBS patients
• Reduced diversity and altered bacterial ratios
• Small intestinal bacterial overgrowth (SIBO) overlaps with IBS in some patients
• Explains why rifaximin and probiotics help some patients

Why this matters for treatment:

• Visceral hypersensitivity → neuromodulators (TCAs, SNRIs) reduce pain perception
• Altered motility → antidiarrheals (IBS-D) or prokinetics/secretagogues (IBS-C)
• Gut-brain axis → psychological therapies (CBT, hypnotherapy) are effective
• Microbiome → dietary changes (low-FODMAP), rifaximin, probiotics
• Multiple mechanisms → multimodal treatment often needed

How to explain to patients#

Your gut and brain are constantly talking to each other through nerves and chemicals. In IBS, this communication system is overly sensitive—your gut sends stronger signals than normal, and your brain interprets normal sensations as pain or discomfort.

Think of it like a smoke detector that’s too sensitive. A normal smoke detector goes off when there’s a fire. Your gut’s “alarm system” is going off for things that shouldn’t trigger it—normal amounts of gas, normal stretching after a meal, normal contractions that move food along.

This isn’t something you’re imagining, and it’s not “all in your head.” The nerves in your gut are genuinely more sensitive than average. Stress and anxiety can turn up the volume on these signals, which is why symptoms often worsen during stressful times.

The good news is that IBS doesn’t damage your intestines or lead to cancer or other serious diseases. It’s uncomfortable and frustrating, but it’s not dangerous. Treatment focuses on calming down that oversensitive alarm system through diet changes, medications, and sometimes stress management.

Clinical presentation#

Characteristic symptoms#

Core symptoms (required for diagnosis):

• Abdominal pain: crampy, often in lower abdomen; typically improves with defecation
• Altered bowel habits: diarrhea, constipation, or alternating
• Bloating and distension: very common; often worse throughout the day

Symptom patterns by subtype:

Associated symptoms:

• Mucus in stool (common; not alarming in IBS)
• Urgency and fecal incontinence (IBS-D)
• Sensation of incomplete evacuation
• Symptoms worse with stress, certain foods, menstruation
• Symptoms typically spare sleep (nocturnal symptoms suggest organic disease)

Extraintestinal associations (common comorbidities):

• Fibromyalgia (30-70% overlap)
• Chronic fatigue syndrome
• Chronic pelvic pain, interstitial cystitis
• Temporomandibular joint disorder
• Migraine headaches
• Anxiety and depression (40-60% comorbidity)

Physical exam findings#

Usually normal. Physical exam is primarily to identify alarm features or alternative diagnoses.

Findings that may be present:

• Mild diffuse abdominal tenderness (especially LLQ)
• Palpable sigmoid colon (stool-filled in IBS-C)
• Bloating/distension (visible or reported)

Findings that should NOT be present (suggest alternative diagnosis):

• Significant weight loss
• Palpable abdominal mass
• Hepatosplenomegaly
• Lymphadenopathy
• Perianal disease (fistulas, abscesses—suggests Crohn’s)
• Blood on rectal exam

Red flags#

Alarm features requiring additional workup (do not exclude IBS but warrant investigation):

• Unintentional weight loss (>5% in 6 months)
• Rectal bleeding or hematochezia
• Iron deficiency anemia
• Nocturnal symptoms (waking from sleep with diarrhea/pain)
• Age >50 with new-onset symptoms
• Family history of colorectal cancer, IBD, or celiac disease
• Progressive worsening of symptoms
• Fever
• Palpable abdominal mass

Diagnostic workup#

Initial evaluation#

IBS is a positive diagnosis based on Rome IV criteria—not a diagnosis of exclusion.

In patients meeting Rome IV criteria WITHOUT alarm features, limited testing is appropriate:

Recommended baseline tests:

• CBC: rule out anemia
• CRP or ESR: elevated suggests inflammatory condition (IBD)
• Celiac serology: TTG-IgA + total IgA (celiac mimics IBS; 4x more common in IBS patients)
• Fecal calprotectin: distinguishes IBS from IBD
  • <50 μg/g: IBS very likely; IBD essentially ruled out
  • 50-150 μg/g: gray zone; consider repeat or colonoscopy if clinical suspicion

  • 150 μg/g: suggests organic/inflammatory cause; colonoscopy indicated

Additional tests based on presentation:

• TSH: if symptoms suggest thyroid dysfunction
• Stool studies for infection: if recent travel, acute onset, or immunocompromised
• Hydrogen breath test: if SIBO or lactose/fructose intolerance suspected

Confirmatory testing#

Colonoscopy is NOT routinely needed for IBS diagnosis in patients <45 without alarm features.

Indications for colonoscopy:

• Age ≥45 (for CRC screening regardless of IBS)
• Alarm features present
• Elevated fecal calprotectin (>150 μg/g)
• Family history of CRC or IBD
• Refractory symptoms despite treatment
• IBS-D to rule out microscopic colitis (random biopsies needed—mucosa looks normal)

EGD indications:

• Positive celiac serology (for confirmatory duodenal biopsies)
• Upper GI symptoms (dyspepsia, early satiety)
• Suspected SIBO (duodenal aspirate)

Interpretation of normal colonoscopy:

• Confirms absence of structural disease
• Does NOT rule out microscopic colitis (need random biopsies)
• Supports IBS diagnosis in appropriate clinical context

When to refer for specialist workup#

GI referral indications:

• Alarm features requiring colonoscopy
• Elevated fecal calprotectin (>150 μg/g)
• Positive celiac serology
• Refractory symptoms despite 3-6 months of first-line treatment
• Diagnostic uncertainty
• Suspected microscopic colitis (IBS-D with watery diarrhea, older patient)
• Need for specialized testing (anorectal manometry, motility studies)

Specific referral thresholds:

• Fecal calprotectin >150 μg/g → colonoscopy
• TTG-IgA positive → EGD with duodenal biopsies
• IBS-D not responding to loperamide + dietary changes after 8 weeks → GI evaluation
• IBS-C not responding to fiber + osmotic laxatives after 8 weeks → consider secretagogues or GI referral

What NOT to order#

Avoid these tests in routine IBS:

• Colonoscopy in patients <45 without alarm features (low yield; reinforces illness behavior)
• Abdominal CT or MRI (does not diagnose IBS; incidental findings cause anxiety)
• Food allergy panels (IgG food sensitivity tests are not validated; waste of money)
• Comprehensive stool analysis (not evidence-based)
• Repeated colonoscopies (once normal, no need to repeat unless new alarm features)
• Extensive autoimmune panels
• Gastric emptying study (unless gastroparesis specifically suspected)

Cost considerations:

• Colonoscopy: $1,000-3,000; reserve for appropriate indications
• Fecal calprotectin: $50-150; cost-effective to avoid unnecessary colonoscopy
• Food sensitivity panels: $200-500; not recommended (no evidence)
• Excessive testing increases healthcare costs and patient anxiety without improving outcomes

Treatment#

Goals of therapy#

Symptom control:

• Reduce abdominal pain frequency and severity
• Normalize bowel habits (not necessarily daily BMs—patient’s comfortable baseline)
• Reduce bloating and distension
• Improve quality of life

Functional goals:

• Ability to work and socialize without symptom interference
• Reduced anxiety about symptoms
• Dietary flexibility (not overly restrictive)
• Reduced healthcare utilization

Realistic expectations:

• IBS is chronic; goal is management, not cure
• Symptoms will wax and wane
• 50-70% improvement is a reasonable target
• Complete symptom resolution is uncommon

Non-pharmacologic management#

Dietary modifications (first-line for all subtypes):

Low-FODMAP diet:

• Effective in 50-80% of patients; strongest evidence of any dietary intervention
• FODMAPs = Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols
• High-FODMAP foods: wheat, onions, garlic, beans, lactose, apples, pears, honey, artificial sweeteners
• Implementation: strict elimination for 2-6 weeks, then systematic reintroduction
• Refer to dietitian experienced in low-FODMAP for best results
• Counsel: “This is not a forever diet—we eliminate, then reintroduce to find YOUR triggers”

Other dietary approaches:

• Lactose elimination: trial if lactose intolerance suspected
• Gluten reduction: some patients improve even without celiac (non-celiac gluten sensitivity)
• Fiber modification: increase soluble fiber (psyllium) for IBS-C; may worsen bloating initially
• Avoid gas-producing foods: beans, cabbage, carbonated beverages
• Small, frequent meals: reduces postprandial symptoms
• Limit caffeine and alcohol: can trigger symptoms

Lifestyle modifications:

• Regular physical activity: improves symptoms and reduces stress
• Adequate sleep: sleep deprivation worsens symptoms
• Stress management: stress is a major trigger; relaxation techniques help
• Regular meal timing: establishes predictable gut patterns

Psychological therapies (strong evidence):

• Cognitive behavioral therapy (CBT): NNT ~4; as effective as medications
• Gut-directed hypnotherapy: NNT ~4; sustained benefit
• Mindfulness-based stress reduction
• Consider for: refractory symptoms, significant anxiety/depression, patient preference
• Counsel: “These aren’t because it’s ‘in your head’—they work by calming the gut-brain connection”

Pharmacologic management#

IBS-D (Diarrhea-predominant):

IBS-C (Constipation-predominant):

Antispasmodics (for cramping/pain, all subtypes):

Neuromodulators (for pain-predominant, all subtypes):

Probiotics:

• Evidence is mixed; some strains show benefit, others don’t
• Bifidobacterium infantis 35624 (Align): best evidence for IBS
• VSL#3: some evidence for bloating
• Trial for 4-8 weeks; discontinue if no benefit
• Counsel: “Probiotics may help some people, but we don’t know which strains work best for which patients”

Patient counseling points#

For diagnosis:

• “IBS is a real medical condition—it’s not ‘all in your head.’ The nerves in your gut are more sensitive than normal.”
• “IBS doesn’t damage your intestines and doesn’t lead to cancer or other serious diseases.”
• “This is a chronic condition that we manage, not cure. Symptoms will come and go.”

For dietary changes:

• “The low-FODMAP diet works for most people, but it’s not meant to be forever. We eliminate foods, then add them back to find YOUR specific triggers.”
• “Keep a food diary for 2 weeks before we start—it helps identify patterns.”
• “Work with a dietitian if possible—they can guide you through the elimination and reintroduction phases.”

For medications:

• “Loperamide is safe to use regularly—it’s not habit-forming and won’t make your gut ’lazy.’”
• “Antidepressants at low doses work on gut nerves, not just mood. We’re using them for pain, not depression.”
• “Give medications 4-6 weeks to work. If one doesn’t help, we have other options.”

For lifestyle:

• “Stress doesn’t cause IBS, but it definitely makes it worse. Finding ways to manage stress can really help your symptoms.”
• “Regular exercise helps—even a daily walk can improve gut function.”

Monitoring and follow-up#

Initial treatment phase:

• Follow-up at 4-6 weeks to assess response
• If dietary changes initiated: assess adherence, symptom response
• If medication started: assess efficacy, side effects

Ongoing management:

What to monitor:

• Symptom severity (consider validated questionnaire: IBS-SSS)
• Quality of life impact
• Medication side effects
• Weight (unintentional loss is alarm feature)
• Development of new symptoms or alarm features

When to reassess diagnosis:

• New alarm features develop
• Symptoms change character significantly
• No response to multiple appropriate treatments
• Patient >50 with worsening symptoms

Patient education#

What is this condition?#

IBS stands for irritable bowel syndrome. It is a common condition that affects how your gut works. About 1 in 10 people have IBS.

In IBS, the nerves in your gut are extra sensitive. Normal things like gas, food moving through, or a full bowel can cause pain or discomfort. Your gut may also move too fast (causing diarrhea) or too slow (causing constipation).

IBS is not dangerous. It does not damage your intestines. It does not turn into cancer or other serious diseases. But it can be uncomfortable and frustrating to live with.

We do not know exactly what causes IBS. It often runs in families. It can start after a stomach infection. Stress and anxiety can make symptoms worse, but they do not cause IBS.

What you can do#

Keep a food diary. Write down what you eat and when you have symptoms. This helps find your triggers.

Try the low-FODMAP diet. This means avoiding certain foods that can cause gas and bloating. Your doctor or a dietitian can give you a list. You avoid these foods for a few weeks, then add them back one at a time to find which ones bother you.

Eat smaller meals. Large meals can trigger symptoms. Try eating 5-6 small meals instead of 3 large ones.

Drink plenty of water. This is especially important if you have constipation.

Exercise regularly. Even a 20-30 minute walk each day can help your gut work better.

Manage stress. Stress makes IBS worse. Try deep breathing, meditation, or other relaxation techniques.

Take your medicines as directed. Some work best when taken before meals. Others work best at bedtime.

When to seek care#

Call your doctor if you have:

• Blood in your stool
• Weight loss without trying
• Symptoms that wake you up at night
• Fever
• Symptoms that are getting much worse
• New symptoms that are different from your usual IBS

Go to the emergency room if you have:

• Severe abdominal pain that does not go away
• Vomiting and cannot keep fluids down
• Signs of dehydration (dizziness, dark urine, confusion)
• Large amounts of blood in your stool

Questions to ask your doctor#

• What type of IBS do I have (diarrhea, constipation, or mixed)?
• Should I try the low-FODMAP diet? Can I see a dietitian?
• What medicines might help my symptoms?
• Are there side effects I should watch for?
• How long should I try a treatment before we know if it works?
• Should I see a gastroenterologist?
• Could my symptoms be caused by something else?
• Are there any tests I need?

Prognosis and monitoring#

Expected course#

With treatment:

• 50-70% of patients achieve meaningful symptom improvement
• Symptoms typically wax and wane over time
• Subtype may change (IBS-D → IBS-M → IBS-C)
• Many patients learn to manage symptoms effectively with diet and lifestyle
• Complete symptom resolution is uncommon but possible

Without treatment:

• Symptoms persist in most patients
• Quality of life significantly impacted
• Increased healthcare utilization (repeated visits, unnecessary tests)
• Higher rates of anxiety and depression

Natural history:

• IBS is chronic but not progressive
• Does NOT increase risk of colorectal cancer, IBD, or mortality
• Symptoms may improve with age in some patients
• Post-infectious IBS may resolve over 2-3 years in some cases

Monitoring parameters#

Complications to watch for#

IBS itself does not cause complications, but watch for:

Misdiagnosis concerns:

• Celiac disease: 4x more common in IBS patients; screen with TTG-IgA
• Microscopic colitis: presents like IBS-D; requires colonoscopy with biopsies
• IBD: can initially present like IBS; watch for alarm features
• Colorectal cancer: rare but important; age-appropriate screening

Treatment-related:

• Loperamide overuse: rare but can cause constipation, ileus
• TCA side effects: constipation, dry mouth, urinary retention, cardiac effects
• Restrictive eating: overly strict diets can lead to nutritional deficiencies
• Opioid use: avoid; can cause narcotic bowel syndrome

Psychological:

• Anxiety and depression: common comorbidities; screen and treat
• Catastrophizing: excessive worry about symptoms
• Healthcare-seeking behavior: repeated unnecessary testing

Special populations#

Elderly/geriatric#

Presentation differences:

• New-onset IBS uncommon after age 50—consider organic causes first
• May present with constipation-predominant symptoms
• Symptoms may overlap with medication side effects

Treatment considerations:

• Avoid anticholinergic medications (dicyclomine, hyoscyamine)—Beers criteria
• TCAs: use with caution; start lower doses (10 mg); monitor for anticholinergic effects, falls, cardiac effects
• Loperamide: safe but monitor for constipation
• Linaclotide, plecanatide: safe; no dose adjustment needed
• Prucalopride: reduce to 1 mg daily in elderly

Beers criteria medications to avoid or use with caution:

• Dicyclomine, hyoscyamine (anticholinergic)
• TCAs at higher doses (anticholinergic, falls, cardiac)
• Diphenoxylate/atropine (anticholinergic)

Workup considerations:

• Lower threshold for colonoscopy in new-onset symptoms
• Consider microscopic colitis (more common in elderly)
• Review medications carefully (many cause GI symptoms)

Chronic kidney disease#

Dosing adjustments:

• Loperamide: no adjustment needed
• Linaclotide: no adjustment needed (minimal systemic absorption)
• Plecanatide: no adjustment needed
• Lubiprostone: no adjustment needed
• Prucalopride: 1 mg daily if eGFR <30
• TCAs: use with caution; may accumulate
• Rifaximin: no adjustment (minimal absorption)

Monitoring:

• Electrolytes if using osmotic laxatives (PEG, lactulose)
• Avoid magnesium-containing laxatives if eGFR <30

Special considerations:

• CKD patients often have constipation from phosphate binders, iron
• May have altered gut motility from uremia
• Higher rates of SIBO

Other populations#

Pregnancy:

• IBS symptoms may worsen, improve, or stay the same during pregnancy
• First-line: dietary modifications, fiber, lifestyle
• Loperamide: limited data; generally avoided in first trimester; may use in 2nd/3rd trimester if needed
• PEG: considered safe; first-line for constipation in pregnancy
• Avoid: linaclotide, lubiprostone, eluxadoline (insufficient data)
• TCAs: discuss risks/benefits; some data on safety but generally avoided

Anxiety/depression comorbidity:

• 40-60% of IBS patients have comorbid anxiety or depression
• Treat both conditions—improvement in one often improves the other
• SSRIs: may help anxiety/depression but can worsen diarrhea (IBS-D) or cause constipation
• SNRIs (duloxetine): good choice for IBS with comorbid anxiety/depression and pain
• TCAs: help IBS symptoms AND depression at higher doses
• Consider CBT or gut-directed hypnotherapy

Polypharmacy considerations:

• Review all medications for GI side effects
• Common culprits: metformin (diarrhea), opioids (constipation), anticholinergics (constipation), PPIs (may increase SIBO risk)
• Drug interactions:
  • TCAs + anticholinergics: additive effects
  • Eluxadoline + opioids: avoid combination
  • Alosetron + fluvoxamine: contraindicated (CYP1A2 inhibition)

Post-infectious IBS:

• Develops in 10-15% after acute gastroenteritis
• More common after bacterial infections (Campylobacter, Salmonella, Shigella)
• Usually IBS-D subtype
• May resolve over 2-3 years in some patients
• Treatment same as other IBS

When to refer#

Specialist referral criteria#

GI referral:

• Alarm features present (weight loss, bleeding, anemia, nocturnal symptoms)
• Elevated fecal calprotectin (>150 μg/g)
• Positive celiac serology
• Age ≥45 needing colonoscopy for CRC screening
• Refractory symptoms despite 3-6 months of appropriate treatment
• Suspected microscopic colitis
• Diagnostic uncertainty
• Need for specialized testing (anorectal manometry, motility studies)
• Consideration for restricted medications (alosetron)

Psychology/psychiatry referral:

• Significant anxiety or depression affecting function
• Interest in CBT or gut-directed hypnotherapy
• Catastrophizing or excessive illness behavior
• Refractory symptoms with strong psychological component

Dietitian referral:

• Low-FODMAP diet implementation
• Nutritional concerns from restrictive eating
• Complex dietary triggers

Urgency levels#

Smartphrase snippets#

IBS, stable/controlled: IBS-[D/C/M] on [current regimen] with good symptom control, no alarm features. Continue dietary modifications and [medications]; f/u 6-12 months or PRN for flares.

IBS, worsening/uncontrolled: IBS-[D/C/M] with inadequate control on current regimen, no new alarm features. Plan: [add/change medication], reinforce low-FODMAP adherence; GI referral if no improvement in 4-6 weeks.

IBS, new diagnosis: Chronic abdominal pain meeting Rome IV for IBS-[D/C/M], no alarm features. Ordered CBC, celiac serology, fecal calprotectin; initiated [dietary modifications/loperamide/PEG]; f/u 4-6 weeks.

IBS with alarm features: Chronic GI symptoms with [alarm feature], does not meet straightforward IBS criteria. Ordered [colonoscopy/labs]; GI referral placed for evaluation.

Related pages#

• Diarrhea (Chronic) (complaint) — symptom-based approach to chronic diarrhea including IBS-D differential
• Constipation (complaint) — symptom-based approach to constipation including IBS-C differential
• Abdominal Pain (Chronic) (complaint) — symptom-based approach to chronic abdominal pain including functional GI disorders
• GERD (problem) — often comorbid with IBS; overlapping functional GI disorders
• Generalized Anxiety Disorder (problem) — common comorbidity; treating anxiety often improves IBS
• Major Depressive Disorder (problem) — common comorbidity; TCAs and SNRIs treat both conditions
• Hypothyroidism (problem) — thyroid dysfunction can cause GI symptoms mimicking IBS